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InﬂammationThe inﬁltration of leukocytes into the central nervous system (CNS) is an essential step in the
neuropathogenesis of multiple sclerosis (MS). Leukocyte extravasation from the bloodstream is a multistep
process that depends on several factors including ﬂuid dynamics within the vasculature and molecular
interactions between circulating leukocytes and the vascular endothelium. An important step in this cascade
is the presence of chemokines on the vascular endothelial cell surface. Chemokines displayed along the
endothelial lumen bind chemokine receptors on circulating leukocytes, initiating intracellular signaling
that culminates in integrin activation, leukocyte arrest, and extravasation. The presence of chemokines at
the endothelial lumen can help guide the movement of leukocytes through peripheral tissues during
normal immune surveillance, host defense or inﬂammation. The expression and display of homeostatic or
inﬂammatory chemokines therefore critically determine which leukocyte subsets extravasate and enter the
peripheral tissues. Within the CNS, however, inﬁltrating leukocytes that cross the endothelium face additional
boundaries to parenchymal entry, including the abluminal presence of localizing cues that prevent egress
from perivascular spaces. This review focuses on the differential display of chemokines along endothelial
surfaces and how they impact leukocyte extravasation into parenchymal tissues, especially within the CNS. In
particular, the display of chemokines by endothelial cells of the blood brain barrier may be altered during CNS
autoimmune disease, promoting leukocyte entry into this immunologically distinct site. Recent advances in
microscopic techniques, including two-photon and intravital imaging have provided new insights into the
mechanisms of chemokine-mediated capture of leukocytes within the CNS.edicine, Division of Infectious
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The inﬁltration of leukocytes into the central nervous system
(CNS) is an essential step in the neuropathogenesis of multiple
sclerosis (MS). Leukocyte extravasation from the bloodstream is a
multistep process that depends on several factors including ﬂuid
dynamics within the vasculature and molecular interactions between
circulating leukocytes and the vascular endothelium. An important
step in this cascade is the presence of chemokines on the vascular
endothelial cell surface. Chemokines displayed along the endothelial
lumen bind chemokine receptors on circulating leukocytes, initiating
intracellular signaling that culminates in integrin activation, leuko-
cyte arrest, and extravasation. The presence of chemokines at the
endothelial lumen can help guide the movement of leukocytes
through peripheral tissues during normal immune surveillance, host
defense or inﬂammation. The expression and display of homeostaticor inﬂammatory chemokines therefore critically determines which
leukocyte subsets extravasate and enter peripheral tissues.Within the
CNS, however, inﬁltrating leukocytes that cross the endothelium face
additional boundaries to parenchymal entry, including the abluminal
presence of localizing cues that prevent egress from perivascular
spaces. This review focuses on the differential display of chemokines
along endothelial surfaces and how they impact leukocyte ex-
travasation into parenchymal tissues, especially within the CNS. In
particular, the display of chemokines by endothelial cells of the blood
brain barrier may be altered during CNS autoimmune disease,
promoting leukocyte entry into this immunologically distinct site.
Recent advances in microscopic techniques, including two-photon
and intravital imaging have provided new insights into the mechan-
isms of chemokine-mediated capture of leukocytes within the CNS.
2. CNS vascular compartments
2.1. Vascular anatomy
Homeostasis of the CNS is maintained within strict limits by sev-
eral specializations, both anatomical and immunological, that prevent
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parenchymal tissue. These anatomical specializations consist of a
series of barriers, including the blood–cerebrospinal ﬂuid (CSF) barrier
that prevents free exchange of solutes between the blood and
cerebrospinal ﬂuid [1–3]. The blood–CSF barrier is due not to the
presence of a specialized vascular endothelium, but rather to the
presence of the choroid plexus epithelium inwhich the cells are linked
by tight junctions and are responsible for secreting CSF into the
brain ventricles. The blood brain barrier (BBB), which consists of the
endothelial cells of the cerebral microvasculature and surrounding
pericytes and astrocytic endfeet, has been well characterized in terms
of its morphological and biochemical specializations [2].
While the BBB is typically described as a monolithic entity, there
is accumulating evidence of heterogeneity within the BBB [4] that
varies dependingon the vascular bed aswell as the anatomical location
of the blood vessels. This heterogeneity is evident in the peripheral
vasculature aswell and has been shown in gene expressionmicroarray
analysis comparing blood vessels of different organs, different caliber
vessels, arteries and veins [5], blood vessels and lymphatic vessels
[6], and tumor angiogenesis [7]. Relatively less is known about the
differences within the cerebral vascular bed; however there appear
to be differences in the expression of transporters between different
caliber vessels. The efﬂux transporter P-glycoprotein has been found
in cerebral capillaries but not in parenchymal or superﬁcial venules
and arterioles [8], while differences in the expression of the Glut-1
transporter and the Transferrin receptor between different size
cerebral vessels has also been noted [4].
The heterogeneity of the vascular endothelium extends to the
structural make-up of interendothelial junctions. In early studies, the
organization of interendothelial protein strands was found to vary
between arterioles, capillaries and venules in the periphery [9,10].
Freeze fracture investigations revealed that arterioles and capillaries
displayed complex, continuous junctional strands while junctional
strands were fewer andmore loosely organized in venules. Consistent
with these observations, Nagy et al. observed that tight junctions
of post-capillary brain venules were discontinuous and less complex
than those of brain capillaries [11].
Conﬁrmation of these anatomical observations was provided by
electrophysiological studies showing that in situ transendothelial
electrical resistance (TEER) across rat pial arterioles were signiﬁcantly
higher than resistances measured across pial venules (mean values
of 2050 and 800 Ω cm2 respectively) [12,13], suggesting that arteriole
tight junctions are more complex, as TEER values correlate positively
with tight junction strand number and complexity [14,15]. In ad-
dition, these studies highlight the fact that results of studying
electrophysiological and ultrastructural features of pial microvessels
may differ from those obtained by examining deeper cerebral cortical
microvessels. Allt and Lawrenson reviewed the morphological and
molecular differences between pial microvessels and cerebral cortical
microvessels [16] and conclude that there are many similarities
between these two types of vessels. The authors do note however that
tight junctions between cerebral microvascular endothelial cells were
marked by consistent fusion of adjacent endothelial cell membranes,
while the majority of endothelial cell junctions in pial microvessels
were typiﬁed by membrane separation at the interendothelial cell
cleft. Notably, parenchymal but not pial vessels were invested with
astrocyte endfeet of the glial limitans. It is not clear at this time
what effect, these differences might have on the barrier properties of
microvessels in these CNS compartments.
While there appear to be parallels between pial and parenchymal
microvessels, there is a differential display of adhesion molecules
involved in leukocyte extravasation between more superﬁcial pial or
meningeal vessels and parenchymal vessels of the brain and spinal
cord. Speciﬁcally, P- and E-selectin have been detected in micro-
vessels of the subarachnoid space, primarily in venules, but not in the
deeper parenchymal vessels [17]. This differential pattern of expres-sion is consistent with reports of P-selectin mediated rolling of T-cells
along meningeal vessels [18,19] but not along the vessels within
the spinal cord white matter where leukocytes do not roll but rather
undergo immediate arrest [20]. Some studies have also suggested
that regional differences in BBB chemokine expression are important
determinants of leukocyte extravasation. In particular, polarized ex-
pression of the chemokine CXCL12 at the abluminal endothelial
membrane has been identiﬁed in both parenchymal arterioles and
venules, but CXCL12 relocation in MS and EAE appears to occur
exclusively at the level of the post-capillary venule and correlates
strongly with the perivascular inﬁltration of T-cells [21,22]. The
reasons for BBB heterogeneity remain unclear, but may relate to
functional requirements for different regions of the vascular bed
including immune effector responses and the initiation of parenchy-
mal inﬂammation.
2.2. CNS immune privilege
The concept of immune privilege developed as a result of studies
ﬁnding that antigenic material, including foreign tumors and tissue
grafts, failed to elicit a systemic, T-cell mediated immunological re-
sponse when transplanted into certain tissues including the brain
parenchyma and corneal tissue (reviewed in [23,24]). Subsequent
studies conﬁrmed that in addition to xenografts, the immune priv-
ilege of the CNS extended to include bacteria, viruses, and viral vectors
[25–28]. These observations correlate teleologically with the limited
regenerative capacity of the CNS, where tissue injury from an inﬂam-
matory response is potentially more damaging than in the periphery.
Further, the brain parenchyma is encased within an inexpandable
skull and therefore has no ability to accommodate changes in volume
brought about by cellular inﬁltrates and/or swelling.
Presently it is recognized that the CNS immune privilege is not
absolute and that foreign material implanted within the CNS can elicit
an immune response, albeit one that is delayed and more carefully
regulated than in the periphery [1]. In this sense, the CNS is more
accurately described as an immunologically specialized site rather
than immunologically privileged.
Interestingly, the location of the foreign material within the CNS
has a signiﬁcant effect on the severity of the immune response.
The intensity of immune responses increases with proximity to the
ventricles of the brain [29–32], and materials implanted within the
subarachnoid space and meninges are capable of eliciting a robust
immune response. The propensity of these sites to elicit a typical
peripheral immune response suggests that the ventricular and sub-
arachnoid CSF may function as sites of physiological immune
surveillance. Consistent with this hypothesis, cellular inﬁltrates that
accumulate within the meningeal membranes have been observed to
arrange structures resembling secondary lymphoid structures [33],
while inﬁltrates within the parenchyma do not exhibit the features
of lymphoid neogenesis. More recently, Kivisakk et al. have shown
that CD4+ T-cells are restimulated within the subarachnoid space by
encounters with MHC class II+ antigen presenting cells prior to the
onset of inﬂammation in a murinemodel of CNS autoimmune disease,
experimental autoimmune encephalomyelitis (EAE), providing fur-
ther support to the concept of the subarachnoid space and meninges
as a site of routine immunological surveillance [34].
3. Chemokines displayed on the surfaces of post-capillary venules
lead to the arrest, activation and adhesion of rolling leukocytes
Contact between circulating leukocytes and vascular endothelium
is initially promoted by ﬂuid dynamics within blood vessels during a
process called margination [35,36]. Leukocyte margination describes
the phenomenon whereby leukocytes ﬂowing in a blood vessel tend
to be positioned close to the vascular wall rather than within
the rapidly ﬂowing center of the vessel. This phenomenon occurs
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ﬂows relatively slowly. Further, red blood cells aggregate in the center
of the vessel, displacing leukocytes to the periphery where the ﬂow
velocity is much lower [35,37,38]. Leukocytes at the blood–endothe-
lium interface exhibit enhanced intercellular interactions, facilitating
contact and tethering of leukocytes to the endothelial wall.
Rolling along the vascular wall slows the circulating lymphocytes
considerably and permits the sampling of the lumenal surface of the
endothelial cells, leading to activation of integrins on leukocytes
resulting in adhesion strengthening and ﬁrm arrest [36,39,40]. Signals
to activate integrins are transduced from the vascular wall to the
rolling leukocyte by chemokines displayed on the endothelial lumen.
Chemokines bind their receptors on the leukocyte surface and initiate
G-protein coupled signaling that results in increased integrin binding
afﬁnity as well as clustering at the cell surface [40–43]. Integrin
activation leads to enhanced avidity of the adhesion molecule for its
endothelial ligands which include members of the Ig-superfamily,
speciﬁcally VCAM-1 and ICAM-1, as well as ﬁbronectin CS1 epitope
(FNCS1).
Chemokines are secreted molecules and are often described in
terms of their ability to induce cellular migration along a chemotactic
gradient. This idea implies that chemokines present within blood or
interstitial ﬂuid form soluble gradients that drive cell movement. In
tissues however, chemokines are more commonly associated with
extracellular matrix components or bound to cell surface proteogly-
cans [44,45]. In this context, the differential display of chemokines
along the endothelial surface in association with proteoglycans can
provide arrest and migration cues that drive leukocyte migration.3.1. Transendothelial migration can occur via two pathways
Integrin mediated adhesion of circulating lymphocytes to the
vascular endothelium is followed by crawling along and then ex-
travasation across the vascular wall. This transmigration step leads to
the accumulation of lymphocytes in the perivascular space of the CNS
and can occur via paracellular pathways between adjacent endothelial
cells or directly through the endothelial cell itself via transendothelial
migration. The mechanisms of endothelial transmigration in the
peripheral vasculature have been studied intensively and much is
now known concerning the interactions between adhesion molecules
on extravasating leukocytes and the molecules that make up the
interendothelial junctions (for review see [46,47]).
Platelet endothelial cell adhesion molecule-1 (PECAM-1 or CD31)
is a transmembrane protein expressed at interendothelial junctions
as well as on neutrophils, monocytes and some subsets of T-cells.
PECAM-1 appears to play a role in guiding leukocytes to inter-
endothelial junctions. In vitro and in vivo studies utilizing PECAM-1
blocking antibodies have demonstrated that blocking homophilic
interactions between PECAM-1 on circulating leukocytes and endo-
thelial cells causes leukocytes to accumulate at the apical side of
the endothelium or on the abluminal side between the endothelium
and the basement membrane [48–51]. The location of immune cell
accumulation in these studies appears to depend upon homophilic
interactions between different Ig domains of the PECAM-1 protein
located on the lumenal and abluminal side of the endothelium.
More recently the protein CD99, ubiquitously expressed on by
leukocytes, has been identiﬁed at the apical surface of endothelial
cells and also at interendothelial junctions. In vitro studies with
HUVEC monolayers demonstrated that anti-CD99 blocking antibodies
cause monocytes to accumulate between endothelial adjacent endo-
thelial cells, with a portion of the monocyte visible on the apical side,
while a portion of the monocyte was also detectable on the abluminal
side between the endothelium and basement membrane [52,53].
These results suggest that the expression of CD99 and PECAM-1 along
the lumenal endothelial surface and at interendothelial junctions maybe responsible for guiding leukocytes to and through the paracellular
pathway.
While many of the relevant molecules in the transmigration
cascade have been identiﬁed, at present it is not clear to what extent
these molecules mediate passage through the transcellular versus
the paracellular pathways [54]. Many of the adhesion molecules
relevant for transendothelial migration are expressed at the lumenal
endothelial surface as well as at the interendothelial cell junctions
(PECAM-1, CD99, and ICAMs), making their relative contributions to
these two pathways obscure. Other molecules, such as the junctional
adhesion molecules (JAMs), ESAM, and VE-cadherin are expressed
exclusively at endothelial cell junctions and may contribute solely to
paracellular transmigration. The relative contribution of these path-
ways, remains to be determined, but likely depends upon numerous
variables including the type of leukocyte extravasating, location
within the vascular bed, the target tissue, and the initiating stimulus
for transmigration.
Within the CNS, leukocyte entry across the endothelium can
take place via the transcellular pathway, leaving interendothelial cell
junctions intact [55,56]. This may be due to the specializations of the
endothelial tight junctions at the BBB, where the transmembrane
protein strands comprising the junctional domain are more numerous
and complex than in the peripheral tissues [11,57]. T-cells within
the CNS interact with the vascular wall either by rolling (superﬁcial,
andmeningeal microvessels) or immediate capture (spinal cordwhite
matter microvessels), However, T-cell transmigration appears to
occur exclusively at the levels of the post-capillary venule. The reason
for this speciﬁcity is not known but may relate to heterogeneity of the
BBB with regard to anatomical organization, complexity of the tight
junctions and expression of chemokines by the endothelium [4,58].
The activation state of the vasculature in different brain regions
may also be an important determinant of the location of T-cell
transmigration. Kivisakk et al. have shown that P- and E-selectin
are expressed on meningeal vessels but not parenchymal vessels
in humans both with and without CNS inﬂammation [17]. Further,
CD4+ T-cells are restimulated by interactions with antigen present-
ing cells within the subarachnoid space during the early phases of
EAE, followed by their proliferation and accumulation within the
subarachnoid space and appearance within the spinal cord paren-
chyma at the onset of EAE signs [34]. Together these studies support
the idea that the differential expression of adhesion molecules might
direct leukocyte transmigration across superﬁcial subarachnoid blood
vessels into the subarachnoid space as an early event during immune
effector responses within the CNS [59,60].
4. Chemokine expression at endothelial cell barriers outside the
CNS: lessons from lymphoid and visceral tissues
The expression patterns of endothelial cell chemokines depend
on their cellular sources and whether they are translocated from
abluminal to lumenal surfaces of venules where they can exert actions
towards circulating leukocytes. A critical aspect of chemokine
function, therefore, is their localization along endothelial cell surfaces
and extracellular matrix. In this section, we will discuss the evidence
that immobilized chemokines play a role in leukocyte selection
for entry and response within lymphoid and visceral tissues during
immune surveillance and in response to inﬂammatory cues.
4.1. Chemokine display in lymphoid tissues
The discovery of chemokines as agents of leukocyte mobility and
directed migration led to numerous in vitro analyses examining
the movement of cells towards increasing concentrations of soluble
chemokines using Boyden chambers [61]. Although these studies
were critical for elucidating many aspects of chemokine biology, they
fostered the notion that leukocytes respond to soluble chemokine
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endothelium and extracellular matrix direct rolling leukocytes to
ﬁrmly adhere to the endothelium through integrin activation [62].
Interactions with surface matrix molecules are believed to provide
a mechanism to concentrate and localize chemokines, preventing
their rapid diffusion into blood and tissue ﬂuids with subsequent loss
of immunological effects [63]. Also, because sheer stress, as demon-
strated by experiments performed under physiological ﬂow condi-
tions [64–66], is critical for chemokine-mediated integrin activation,
arrest and crawling of leukocytes, chemokine immobilization is likely
to be crucial for the recruitment of leukocytes across endothelial
cell barriers.
Although the extracellular matrix molecules responsible for che-
mokine binding are unknown, chemokines are highly basic proteins,
which typically interact well with glycosaminoglycans (GAGs), acidic,
sulfated linear polysaccharides that are major components of
extracellular matrix. Although there are at least six major classes of
GAGs, studies examining chemokine interactions with this group of
molecules have focused primarily on binding to heparin [67]. Many
chemokines contain well-established heparin-binding domains and
exhibit conformational changes upon interaction with heparan sul-
fate proteoglycans [68–70]. In in vitro systems, immobilized heparin
mediates chemokine oligomerization while solubilized heparin dis-
places membrane-associated chemokines from cultured endothelial
cells and decreases the transendothelial migration of T-cells [71,72].
Mutations that inhibit binding to heparin do not affect chemokine
binding to cognate receptors yet diminishes their ability to induce cell
migration in vivo [73–75]. Indeed, systemic heparinization of patients
leads to increased plasma levels of the proinﬂammatory chemokines
CXCL9, CXCL10 and CXCL11, which decrease upon subsequent
administration of the heparin antagonist protamine [72]. Chemokine
classes exhibit rank order of afﬁnity for GAGs and single chemokines
may exhibit different forms of GAG-binding epitopes, suggesting
additional regulatory mechanisms for chemokine display along the
extracellular matrix [67,76]. These data conﬁrm the importance of
chemokine oligomerization and GAG binding and support the notion
that chemokines are not likely to exert their in vivo effects via soluble
concentration gradients.
4.2. Leukocyte recruitment into peripheral tissues
The migration of leukocytes into peripheral tissues relies on the
combined expression of chemokine receptors, adhesion molecules
and lipid chemoattractant receptors. These receptors allow leukocytes
to interact with endothelial cell barriers and gain access to
parenchymal tissues as part of immunosurveillance or control of
pathogens. Several of these adhesion molecules have been shown to
convey tissue-speciﬁc homing properties to memory T-cells, such as
CCR7 and CD62L into lymphoid tissues, cutaneous lymphocyte-
associated antigen (CLA), CCR4 and CCR10 into skin and α4β7
integrin and CCR9 into gut [77]. During inﬂammation, a stereotypical
pattern of adhesion and chemokine receptor expression occurs on
leukocytes that generally match the inﬂammatory-mediated induc-
tion of proinﬂammatory chemokine ligands and adhesion receptors
at endothelial cell barriers. Thus, migration of leukocytes occurs
across inﬂamed endothelium, which display one or more chemokines
immobilized along the lumenal surface via binding to GAGs. In
support of this, inactivation of genes involved in heparin sulfation
resulted in decreased leukocyte extravasation in inﬂammatory
models with a reduction in L-selectin-mediated adhesion and in the
transcytosis and binding of chemokines to endothelial cells [78].
Circulating leukocytes are recruited into inﬂamed tissues mainly in
small vessels such as capillaries and venules. Consistent with this,
chemokine expression is higher in microvascular endothelium than
in aortic endothelial cells. Low shear stress was found to activate
endothelial chemokine production via cell surface heparan sulfates,beta3-integrins, focal adhesion kinase, MAP kinase p38beta, mitogen-
and stress-associated protein kinase-1 [79].
During inﬂammation vascular endothelium in most tissues
upregulate E- and P-selectin and chemokine ligands of chemokine
receptors expressed by cells of both innate and adaptive immune
responses. While some of these chemokines are upregulated at the
mRNA level in response to proinﬂammatory cytokines, the endothe-
lium of certain tissues also stores chemokines within Weibel–Palade
bodies (WPBs). WPBs are organelles that stores molecules, such as
P-selectin, that can be rapidly released in response to inﬂammatory
cues, such as TNF-α, to mediate tethering and rolling of leukocytes.
CXCL8, for example, is found inWPBs of intestinal and nasal mucosal
endothelium, and is rapidly released in response to histamine or
thrombin [80–82]. Although microvascular endothelium within the
CNS does not contain stored P-selectin, despite that fact that they
contain WPBs [83,84], IL-1β and TNF-α have been shown to lead to
P-selectin upregulation, providing a means for tethering of leuko-
cytes at the endothelium speciﬁcally during inﬂammatory states.
Chemokines also induce leukocyte movement to interendothelial
junctions where they extend their processes to seek abluminal
chemokines, which then localize transendothelially migrating leu-
kocytes to perivascular sites where GAG-immobilized chemokines
establish haptotactic gradients [66,85].
The endothelial display of several proinﬂammatory chemokines
has been studied in detail. CXCL10 is selectively upregulated by
injured renal microvascular endothelium within tubulointerstitial
area while CCL2 is upregulated at the glomerulus and tubulointer-
stitium, the former correlating with T-cell inﬁltrates and the latter
with monocyte entry at these distinct sites. Anti-CXCL10 antibodies
decreased T-cell inﬁltration and improved renal function [86,87].
DARC is expressed on endothelial cells of capillaries and post-
capillary venules and on epithelial cells within the inﬂamed
synovium, kidney and lung. During inﬂammation, endothelial DARC
is involved in the transport of chemokines from the inﬂamed tissue
to the lumenal side of the endothelium, facilitating leukocyte recruit-
ment and aggravating inﬂammation. In the lung, chemokines are
presented on the pulmonary endothelium, causing neutrophils to
adhere and transmigrate into the lung parenchyma [88]. DARC was
recently shown to limit PMN migration into the alveolar space via
RBC-mediated chemokine sequestration. Use of bone marrow chime-
ric mice using wild-type vs. DARC-deﬁcient mice, however, did not
reveal a role for endothelial cell DARC in leukocyte trafﬁcking [89].
An alternative method of chemokine display along endothelial
surfaces is exhibited by CX3CL1. CX3CL1 is released from the cell
surface by constitutive and inducible protease cleaving [90]. Once
cleaved, CX3CL1 is not captured by the extracellular matrix, suggest-
ing it exerts its effects as a mucin stalk or in solution [91]. CX3CL1 is
expressed by TNF-α- and IL-1-activated endothelium within the
kidney and heart where it induces integrin-independent leukocyte
capture, acting as an adhesion molecule [92–94]. In the CNS, CX3CL1
is expressed by neurons and recent data suggest that it is important
for the recruitment of NK cells at this site [95,96], as discussed later.
5. Expression and function of chemokines and chemokine
receptors at the BBB
Compared to peripheral tissues, less is known regarding the
expression and regulation of lymphoid and inﬂammatory chemokines
within the brain microvasculature. Several homeostatic or lymphoid
chemokines are known to be expressed by the blood vessels of the
CNS, including CCL19, CCL21, and CXCL12 as discussed in detail later.
In contrast to the lymphoid chemokines, the expression of inﬂam-
matory chemokines has not been as well characterized at the human
or murine BBB in vivo, however several inﬂammatory chemokines
have been identiﬁed in in vitro preparations of brain microvascular
endothelial cells including CCL2 [97–99], CCL4 and CCL5 [100]. These
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nuclear cells including CCR1, CCR2, and CCR5 [101]. Use of mice
with targeted deletions of these chemokines and their receptors
revealed a role for CCL2 and CCR2 in the induction of EAE via effects
on inﬁltrating monocytes [102–110]. Studies examining both mice
and individuals without functional CCR5 have excluded a role for
this receptor in susceptibility to EAE (in mice) or MS (in humans)
[111,112]. Further research utilizing in vitro as well as in vivo
approaches is necessary to elucidate the role of inﬂammatory
chemokines in neuroinﬂammation and CNS autoimmunity. The
remainder of this section focuses on the homeostatic chemokines
that have been identiﬁed within the CNS microvasculature and their
potential role in CNS inﬂammation.
5.1. CCR7 and CCL19/CCL21
The chemokines CCL19 and CCL21 are known as homeostatic,
or lymphoid, chemokines due to their role in guiding B-cells, naïve
T-cells, and mature dendritic cells (DCs) into lymphoid tissue under
physiological conditions [113,114]. Within the CNS the expression of
lymphoid chemokines has been examined under normal as well as
neuroinﬂammatory conditions such as MS and its mouse model EAE.
Alt et al., using SJL mice with actively induced EAE, examined the
expression of an array of chemokines in brain and spinal cord tissue
sections [115]. While several chemokines were expressed in
parenchymal tissue and inﬂammatory cells during EAE, only CCL19
mRNA transcripts were constitutively expressed on the endothelial
cells of post-capillary venules in normal as well as EAE brains and
spinal cords. In addition, CCL21 transcripts were induced at post-
capillary venules during EAE. Further, the authors of this study found
that encephalitogenic T-cells stained positively for CCR7 and CXCR3
and that adhesion of these T-cells to frozen sections from EAE brains
was inhibited by preincubation with CCL19 and CCL21. The ex-
pression of these lymphoid chemokines at the BBB and their ability
to attract CCR7 expressing encephalitogenic T-cells led the authors
of this study to speculate that these typically homeostatic chemo-
kines may contribute to maintaining chronic CNS inﬂammation in
EAE.
The role of CCL19 and CCL21 in EAE was further characterized
in relapsing–remitting and chronic relapsing models in SJL and Biozzi
AB/H mice respectively [116]. CCL19 mRNA levels in CNS tissue
homogenates were found to be low under normal condition but
increasedwith disease progression in bothmodels, while CCL21 levels
were low to undetectable under all conditions. Further, CCL19 protein
was expressed by some astrocytes and microglia within the paren-
chyma and immune cells accumulating in the meninges, but not the
endothelial cells of post-capillary venules. CCL21 protein expression
was not detected, except in meningeal vessels of the spinal cord in
some atypical cases in which mice developed chronic stable EAE. The
expression of these lymphoid chemokines in the CNS during EAE led
these authors to suggest that CCL19, and to a lesser extent CCL21, may
function to signal circulating lymphocytes that would normally home
to the lymphoid tissues. The expression of these chemokines during
neuroinﬂammation would then help to retain CCR7 positive T-cells
within the CNS and favor interactionwithmatureDCs. CCL19 andCCR7
interaction in the CNS in EAE may thus be responsible for the local
retention of memory T-cells and contribute to maintaining cycles of
neuroinﬂammation.
Expression of the chemokines CCL19 or CCL21 in transgenic mice
led to CNS inﬂammation when CCL21, but not CCL19, was ectopically
expressed by oligodendrocytes [117]. In mice expressing the CCL21
construct, approximately 70% displayed motor deﬁcits and tremors
and did not survive past 4 weeks, while CCL19 expressing mice
showed no such clinical signs and developed normally. CCL21 ex-
pressing mice were found to have leukocytic inﬁltrates that were
predominantly neutrophils and eosinophils, reactive gliosis of micro-glia and astrocytes, and defects in myelin sheaths that resulted in
hypomyelination of the parenchyma and spinal cord. Interestingly,
expression of CCL21 did not lead to lymphocyte inﬁltration, indicating
that the expression of CCL21 alone is not sufﬁcient to promote
lymphocyte trafﬁcking to the CNS. The ability of CCL21, but not CCL19,
to induce CNS inﬂammation led the authors to speculate that CCL21
may be acting through a distinct chemokine receptor from the shared
CCR7 receptor, possibly through the receptor CXCR3, which can be
expressed by microglia [118–121].
Kivisakk et al. examined the expression of CCR7, CCL19 and CCL21
in brain autopsy material and CSF samples from MS patients [122].
These authors found large numbers of CCR7+ cells in the inﬂamma-
tory cuffs of MS lesions, a subpopulation of which also expressedMHC
type II and CD86, indicating antigen presenting competence and
suggesting that these cells may be maturing DC's. However, in
contrast to previously reported EAE models, CD3 positive T-cells in
acute and chronicMS lesions did not express CCR7. Further, within the
CSF of MS patients the majority (N90%) of T-cells, expressing a central
memory phenotype, also expressed CCR7. In pooled CSF samples of
patients with inﬂammatory neurological diseases, including MS, a
subpopulation of CSF DCs (~33%) expressed CCR7. Overall, however,
DCs comprised about 0.5% of CSF cells. This study also reported
no CCL19 or CCL21 protein expression in endothelial or parenchymal
cells of non-lesioned white matter or in active or chronic MS lesions,
but did ﬁnd strong CCL21 immunoreactivity within the choroid plexus
epithelium. The authors of this paper suggest a model in which
activated microglia and parenchymal macrophages express signals,
including CCR7, associated with maturing DCs. These CCR7 positive
cells are available to restimulate central memory T-cells locally.
Subpial macrophages might also transport myelin associated antigens
from the CNS via the CSF to deep cervical lymph nodes. According to
this scenario, after priming in the periphery, central memory T-cells
enter the CSF, in part via signaling between CCR7 and CCL21 or CCR6
and CCL20 expressed by the choroid plexus epithelium [123,124] and
are stimulated to differentiate into effector type upon restimulation
by APCs within the meninges.
In humans, CCL19 and CCL21 expression levels have also been
determined in tissue samples of patients with neuroinﬂammation
including MS as well as other inﬂammatory neurological disorders
[125]. Under normal conditions, CCL19 transcripts were detected in
brain tissue homogenates, while expression levels were elevated in
homogenates from active and inactive MS lesions. CCL21 expression
levels were very low under all conditions. CCL19 protein levels
in lysates of brain tissue as well as CSF samples were found to be
elevated in MS. Despite the presence of low levels of CCL21 mRNA
transcripts in CNS tissue, no CCL21 protein was detected in brain
tissue lysates or CSF samples from normal or MS patients. The authors
did however report positive CCL21 staining of brain endothelial cells.
The authors of this study attribute the differences in CCL21 expression
levels between human and animal models of disease to the presence
of one CCL21 gene in humans, compared to the presence of 2–3 CCL21
genes in mice. Based on the constitutive expression of CCL19 within
the CNS tissues, the authors speculate that this lymphoid chemokine
may function in physiological immune surveillance of the CNS by
recruiting and retaining CCR7 expressing T-cells. Further the authors
of this study propose that the expression of CCL19 also functions to
recruit other types of immune cells to the CNS including B-cells which
also express the chemokine receptor CCR7.
5.2. CXCR4/CXCR7 and CXCL12
The chemokine CXCL12, or stromal cell-derived factor 1 (SDF-1), is
a potent chemoattractant for monocytes and lymphocytes [126].
CXCL12 is expressed as three alternatively spliced isoforms within the
CNS, with CXCL12α expressed by neurons and CXCL12β and CXCL12γ
expressed by endothelial cells [127]. In the periphery CXCL12 and its
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mune system, as embryonic expression of CXCL12 plays a role in
chemoattraction and proliferation of CXCR4 expressing B- and T-cell
precursors. Similarly, CXCL12 and CXCR4 are involved in patterning
and plasticity of the central nervous system both during development
as well as in themodulation of synapse formation [128]. These parallel
roles for CXCL12 and CXCR4 in immune and nervous system function
suggest an avenue for crosstalk and communication between these
two systems (reviewed by [129]).
Within the central nervous system, the expression patterns for
CXCL12 and CXCR4 are widespread and include the cortex, olfactory
bulb, hippocampus, cerebellum, meninges, and the endothelium of
the BBB. Further, CXCR4 expression has been detected in numerous
types of cells including astrocytes, microglia, oligodendrocytes,
neurons, and endothelial cells of the BBB [130–133]. Interestingly,
these studies have identiﬁed the endothelium of the BBB as a source
of the chemokine ligand CXCL12 as well as its receptor CXCR4,
suggesting a role for CXCL12 in recruiting CXCR4+ circulating
lymphocytes but also a potential feedback mechanism for CXCR4
expressed at the BBB.
Krumbholz et al. identiﬁed CXCL12 protein expression along the
blood vessels of the BBB aswell as in astrocytes and noted that CXCL12
expression was increased in both inactive and active MS lesions [133].
These initial observations of CXCL12 expression at the BBB were
expanded by McCandless et al. who studied the role of CXCL12 at the
BBB of mice in an active immunization model of EAE [22]. CXCL12
message was expressed in unimmunized mice and levels were
signiﬁcantly increased in mice at peak of clinical disease. CXCL12
expression was localized to the vasculature of the spinal cord where
CXCL12 protein was detected along the abluminal surface of theFig. 1. CXCL12 receptors regulate leukocyte access to CNS parenchyma.Within the CNS, CXCL
of endothelial cells under physiological conditions. This abluminal expression pattern of CXC
space, preventing their access to the brain parenchyma proper. In neuroinﬂammatory cond
CXCL12 translocates towards the vessel lumen. CXCR4 and CXCR7 expressing leukocyte
subsequently inducing demyelination. Further, display of CXCL12 along the lumenal endoth
to increased T-cell recruitment and transendothelial migration.endothelial cells of the BBB in unimmunized mice and mice 10 days
post-immunization. In contrast at 14 days post-immunization, during
peak of disease, CXCL12 polarity is lost and its localization shifts
toward a more lumenal expression pattern, which was associated
with dense perivascular inﬁltrates of CXCR4 positive mononuclear
cells. Treatment of mice with the CXCR4 antagonist AMD3100 during
the induction of EAE led to signiﬁcant worsening of disease associated
with more widespread parenchymal inﬁltration, increased demyelin-
ation, and larger lesion areas. Similar studies in a viral model of
encephalitis produced identical results with regard to CXCR4+
leukocyte trafﬁcking, but in this case associated with improved viral
clearance [134]. Taken together these results suggest that abluminal
expression of CXCL12 at the CNS vasculature is important in
restricting the parenchymal access of CXCR4-expressing immune
cells, which are instead localized to perivascular spaces (Fig. 1).
A subsequent study extended these ﬁndings to human neuroin-
ﬂammation, comparing CXCL12 and CXCR4 expression in tissue
specimens from MS and non-MS patients [21]. Similar to mice, in
non-MS patients and uninﬂamed regions of the MS brain, CXCL12
expression was polarized primarily along the parenchymal facing
surface of the endothelial BBB in both arterioles and venules of the
CNS. Consistent with EAE in mice, CXCL12 polarity was lost in CNS
venules of MS patients, with CXCL12 expression shifting from the
abluminal to lumenal endothelial surface, while CXCL12 polarity was
maintained in CNS arterioles. Morphometric analysis indicated that
CXCL12 relocation was associated with the presence of perivascular
inﬁltrates within active MS lesions, which exhibited activated CXCR4,
as detected with an antibody that recognizes the phosphorylated
form of the receptor. The display of CXCL12 was also associated with
the detection of activated CXCR4 on leukocytes within the blood12 expression is localized to the microvasculature along the parenchymal facing surface
L12 functions to retain CXCR4 and CXCR7 expressing leukocytes within the perivascular
itions such as the animal model EAE and in human MS, CXCL12 polarization is lost and
s lose their localizing cues and can inﬁltrate further into the parenchymal tissues
elial surface may provide further signaling to circulating CXCR4/CXCR7+ T-cells leading
226 D.W. Holman et al. / Biochimica et Biophysica Acta 1812 (2011) 220–230(McCandless, Piccio et al. [21]), suggesting that relocation of CXCL12
not only promotes the egress of leukocytes from perivascular spaces
but also increases their capture at the BBB.
Mechanistic details of CXCL12 relocation at the BBB remain
unclear, but recent evidence has pointed to a role for the proinﬂam-
matory cytokine IL-1β [135]. Injection of mice with IL-1β induces
pathologic relocation of CXCL12 at the BBB while injection of TNF-α
does not. Further, IL-1β receptor knockout mice are protected from
EAE and do not exhibit CXCL12 relocation, while TNF-α receptor
knockout mice showed loss of CXCL12 polarity.
Until recently it was believed that CXCL12 mediated its effects
exclusively via interactions with CXCR4, however the receptor CXCR7,
formerly the orphan receptor RDC1, has now been shown to bind
CXCL12 as well as CXCL11 [136,137]. While CXCR7/RDC1 possesses
homology with conserved domains of G-protein coupled receptors
and is structurally similar to other CXC receptors, ligand binding does
not initiate typical intracellular signaling pathways. In particular,
CXCR7 binds CXCL12 with high afﬁnity but ligand binding does not
induce intracellular calcium mobilization or cell migration. However
CXCR7 expression does confer growth and survival advantages
and increased adhesive strength in vitro [137,138]. Other studies
investigating the role of CXCR7 as a signaling receptor have given
conﬂicting results [136,139–143].
Another potential role of CXCR7 in regulating CXCL12 mediated
signaling may involve the ability of CXCR7 to bind to and sequester
CXCL12, regulating local CXCL12 levels in the extracellular space.
Boldajipour et al. demonstrated that CXCR7 expression was critical in
regulating primordial germ cell migration in the developing zebraﬁsh
by its ability to bind and internalize CXCL12 [144,145]. CXCR7 ex-
pression within the somatic environment functioned to sequester
and regulate the extracellular level of CXCL12 and thereby control
the migration of CXCR4 expressing primordial germ cells. Studies
demonstrating such effects in mammals have not been reported.
CXCR7 expression within the CNS of rats was detected via in situ
hybridization, with CXCR7 mRNA transcripts identiﬁed in the
ventricular ependyma, the choroid plexus, neuronal and astroglial
cells as well as cells of the vasculature [146,147]. After cerebral
ischemia, CXCR7 mRNA levels increased along some blood vessels
suggesting that CXCR7may be involved in angiogenesis after ischemia,
a role that would be consistent with previous reports of CXCR7
expression during cardiac development [139] and tumor angiogenesis
[148]. While these studies have identiﬁed the CNS vasculature as a
source of CXCR7 within the CNS, the function of CXCR7 in regulating
lymphocyte trafﬁcking into the central nervous system in normal as
well as pathological conditions remains undeﬁned. Importantly,
CXCR7 expression at the mRNA level is not uniformly followed by
protein production, indicating translational control.
Some clues however may be provided by a recent study by Zabel
et al. that described a role for CXCR7 in regulating CXCL12/CXCR4
mediated transendothelial migration (TEM) [149]. Using human
umbilical vein endothelial cells (HUVECs) grown on transwell mem-
brane inserts, the authors demonstrated that CXCR7 was expressed on
the endothelial surface via ﬂow cytometry, although it was not noted
whether receptor expressionwas restricted to the lumenal or abluminal
side of the cells. TEM assays clearly demonstrated an essential role
for CXCR7 in guiding CXCR4/CXCL12 mediated migration of human
tumor cells expressing both CXCR4 and CXCR7 receptors. Further, the
endogenous ligand CXCL11 or a novel small molecule CXCR7 receptor
antagonist CCX771 were capable of binding endothelial CXCR7 and
inhibiting TEM. Interestingly, although the migration was driven by
CXCR4–CXCL12 interactions, the CXCR7 antagonist CCX771 was more
than 100 times more potent at inhibiting TEM than the CXCR4 receptor
antagonist AMD3100. Taken together these results suggest an important
role for CXCR7 inmediating the TEMof circulating tumor cells.Whether
this receptor plays a similar role in mediating the TEM of circulating
immune cells remains to be determined.5.3. Innate immune cell entry into the CNS
Several chemokines play roles in the recruitment of innate
immune cells including natural killer (NK) cells, neutrophils and
monocytes. NK cells are cytotoxic lymphocytes that destroy cells via
granzyme- and perforin-mediated apoptosis (Yokoyama WM, Altfeld
M, Hsu KC. Biol Blood Marrow Transplant. 2009). NK cells express
several chemokine receptors including CCR4, CCR7, CXCR4, and
CX3CR1 and play important roles in immune responses directed
against tumor and virally infected cells [150]. Studies utilizing the EAE
model indicate that CX3CR1 is required for the trafﬁcking of regulatory
NK cells into the CNS, which refrain disease severity [96]. Consistent
with this, CX3CR1-deﬁciency was recently associated with increased
disease severity in experimental autoimmune uveitis [151]. In
contrast, neutrophil recruitment to the CNS in the setting of EAE is
associated with worsening disease severity [152], promoting leuko-
cyte inﬁltration and extensive demyelination. Neutrophils, granulo-
cytes traditionally associated with clearance of bacterial pathogens,
express CXCR1 and CXCR2, which bind CXCL1 and CXCL2, respective-
ly. Recent studies identifying molecular cues involved in neutrophil
recruitment indicate that Th17 expressed by inﬁltrating CD4+ T-cells
mediates the CNS expression of CXCL1 and CXCL2, which are required
for CNS neutrophil recruitment and induction of EAE [153]. These
authors also demonstrated that neutrophil depletion prevented
induction of EAE and that transfer of wild-type neutrophils into
CXCR2−/− mice, which are resistant to EAE, restored susceptibility.
Chronic over-expression of the inﬂammatory cytokine IL-1β
within the central nervous system using a transgenic mouse model
led to BBB disruption, hippocampal CCL2 expression, and inﬁltration
of leukocytes including T-cells, macrophages, DCs, and neutrophils
[154]. Interestingly, leukocyte entry into the CNS did not lead to overt
neuronal degeneration despite neutrophil inﬁltration that persisted
as long as one year after induction of IL-1β expression. Neutrophil
inﬁltration in this study also coincided with hippocampal upregula-
tion of the neutrophil chemoattractants CXCL1 and CXCL2. Induction
of IL-1β in mice lacking CXCR2, the neutrophil receptor for CXCL1 and
CXCL2, led to a 96% reduction of neutrophil inﬁltration, but did not
signiﬁcantly reduce BBB disruption. Taken together these results
suggest that IL-1β is a potent stimulus for leukocyte inﬁltration to
the CNS including the recruitment of neutrophils, however IL-1β
expression alone is not sufﬁcient to induce neuron inﬂammation or
degeneration.
Within the CNS, microglia act as the main form of immune defense
and share many phenotypical and functional characteristics of
peripheral macrophages [155]. In many CNS pathologies, including
neuroinﬂammation, microglia alter their morphology and phenotype
and proliferate rapidly, a phenomena termed microgliosis [156,157].
While the response of microglia to CNS inﬂammation has been well
characterized, the origin of these cells remains controversial. Many
studies have relied upon bone marrow chimeras produced by
irradiating mice to kill the host's bone marrow cells and injecting
labeled bone marrow cells from a non-irradiated donor. A drawback
to these studies is that injecting bonemarrow cells into the peripheral
circulation may lead to the non-physiological presence of hemato-
poetic precursors persisting within the circulation. Additionally,
irradiation has been shown to lead to the induction of inﬂammatory
cytokines and BBB disruption [158,159] which may permit the entry
of hematopoetic cells that would otherwise be excluded from the CNS.
To circumvent these issues, Ajami et al. used parabiosis to join
the circulatory system of two mice, one of which expressed GFP in
all non-erythroid hematopoetic cells [160]. In parabiotic recipients,
30–40% of the circulating hematopoetic cells became GFP positive.
Despite the presence of GFP positive hematopoetic cells within the
circulation, the authors were unable to demonstrate the presence of
GFP positive microglial cells within the CNS parenchyma under
normal conditions. Additionally, there were no GFP positive cells
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CNS microgliosis, indicating that CNS microglia are capable of rapid
and sustained self-renewal.
Further these authors demonstrated that irradiation of the
parabiotic recipient, but not the donor, did not induce the inﬁltration
of peripheral hematopoetic cells into the CNS. The results of this study
suggest that the presence of donor-derived microglial cells in the
recipient CNS parenchyma reported in previous bonemarrow chimera
studies [161–165]may result from the non-physiological introduction
of bone marrow progenitor cells into the peripheral circulation, along
with cranial irradiation.Mildner et al. investigated the role of radiation
treatment in bone chimera studies using a targeted radiation approach
whereby mice received selective-body radiation that spared the head
[166]. Microglial populations in these protected mice excluded
peripheral blood derived macrophages under normal conditions as
well as during acute microgliosis and chronic neuroinﬂammation
(using cuprizone induced corpus callosum demyelination). Together
the studies by Ajami et al. and Mildner et al. demonstrate that CNS
irradiation is necessary but not sufﬁcient to permit blood myeloid
cells in the periphery to cross the BBB into the CNS and reside as
parenchymal microglia. Finally, in irradiated bone marrow chimeras
and adoptive transfer experiments Mildner et al. identiﬁed peripheral
monocytes expressing Ly-6C and CCR2 as being preferentially
recruited to the CNS during microgliosis and inﬂammation. The
authors identify this monocyte subpopulation as the direct precursor
to parenchymalmacrophages withmicroglial morphology in the adult
brain, suggesting that these cells may be used as vehicles to deliver
genes or other therapeutics across the BBB to the CNS.
6. Concluding remarks
In this review we have outlined the role of chemokines in providing
cues to extravasating leukocytes, directing their movement into
peripheral tissues as well as those of the CNS. The immobilization of
chemokines along the endothelial surface via binding to cell surface
proteoglycans and extracellular matrix proteins provides important
localizing cues for circulating immune cells. Further, the presentation
and translocation of these chemokines between lumenal and abluminal
endothelial surfaces are critical in promoting leukocyte adhesion and
transendothelial migration into secondary lymphoid organs or periph-
eral tissues. Within the CNS, less is known regarding the mechanisms
andmovement of chemokines along the cerebral vasculature in normal
and pathological conditions. Studies on the role of chemokines in
neuroinﬂammation suggest a role for homeostatic chemokines includ-
ing CCL19, CCL21 and CXCL12 in autoimmune disease models, such as
EAE, and in the important neurologic condition MS. CXCL12 expression
in the normal CNS is restricted to the abluminal or parenchymal facing
vascular surface, while in MS CXCL12 translocates toward the vessel
lumen leading to parenchymal inﬁltration and subsequent demyelin-
ation. These studies suggest that abluminal CXCL12 expression may be
important in restricting parenchymal tissue inﬂammation within the
CNS. The role of inﬂammatory chemokines at the CNSmicrovasculature
remains undeﬁned and is primarily limited to in vitro studies.
Regardless, it is clear that the localization of chemokines within the
CNS microvasculature is important in controlling leukocyte access to
parenchyma and themolecularmechanisms regulating themovements
of these chemokines in neuroinﬂammationwill be crucial in developing
novel therapeutics speciﬁcally directed towards diseases of disrupted
immune privilege, such as MS.
References
[1] R.M. Ransohoff, P. Kivisakk, G. Kidd, Three ormore routes for leukocytemigration
into the central nervous system, Nat. Rev. Immunol. 3 (2003) 569–581.
[2] N.J. Abbott, L. Ronnback, E. Hansson, Astrocyte–endothelial interactions at the
blood–brain barrier, Nat. Rev. Neurosci. 7 (2006) 41–53.[3] C.E. Johanson, J.A. Duncan III, P.M. Klinge, T. Brinker, E.G. Stopa, G.D. Silverberg,
Multiplicity of cerebrospinal ﬂuid functions: new challenges in health and
disease, Cerebrospinal Fluid Res. 5 (2008) 10.
[4] S. Ge, L. Song, J.S. Pachter, Where is the blood–brain barrier… really? J. Neurosci.
Res. 79 (2005) 421–427.
[5] J.T. Chi, H.Y. Chang, G. Haraldsen, F.L. Jahnsen, O.G. Troyanskaya, D.S. Chang, Z.
Wang, S.G. Rockson, M. van de Rijn, D. Botstein, P.O. Brown, Endothelial cell
diversity revealed by global expression proﬁling, Proc. Natl. Acad. Sci. U. S. A. 100
(2003) 10623–10628.
[6] S. Podgrabinska, P. Braun, P. Velasco, B. Kloos, M.S. Pepper, M. Skobe, Molecular
characterization of lymphatic endothelial cells, Proc. Natl. Acad. Sci. U. S. A. 99
(2002) 16069–16074.
[7] B. St Croix, C. Rago, V. Velculescu, G. Traverso, K.E. Romans, E. Montgomery, A.
Lal, G.J. Riggins, C. Lengauer, B. Vogelstein, K.W. Kinzler, Genes expressed in
human tumor endothelium, Science 289 (2000) 1197–1202.
[8] D. Virgintino, D. Robertson, M. Errede, V. Benagiano, F. Girolamo, E. Maiorano, L.
Roncali, M. Bertossi, Expression of P-glycoprotein in human cerebral cortex
microvessels, J. Histochem. Cytochem. 50 (2002) 1671–1676.
[9] M. Simionescu, N. Simionescu, G.E. Palade, Segmental differentiations of cell
junctions in the vascular endothelium. Arteries and veins, J. Cell Biol. 68 (1976)
705–723.
[10] M. Simionescu, N. Simionescu, G.E. Palade, Segmental differentiations of cell
junctions in the vascular endothelium. The microvasculature, J. Cell Biol. 67
(1975) 863–885.
[11] Z. Nagy, H. Peters, I. Huttner, Fracture faces of cell junctions in cerebral
endothelium during normal and hyperosmotic conditions, Lab. Invest. 50 (1984)
313–322.
[12] A.M. Butt, H.C. Jones, Effect of histamine and antagonists on electrical resistance
across the blood–brain barrier in rat brain-surface microvessels, Brain Res. 569
(1992) 100–105.
[13] A.M. Butt, H.C. Jones, N.J. Abbott, Electrical resistance across the blood–brain
barrier in anaesthetized rats: a developmental study, J. Physiol. 429 (1990)
47–62.
[14] P. Claude, Morphological factors inﬂuencing transepithelial permeability: a
model for the resistance of the zonula occludens, J. Membr. Biol. 39 (1978)
219–232.
[15] P. Claude, D.A. Goodenough, Fracture faces of zonulae occludentes from “tight”
and “leaky” epithelia, J. Cell Biol. 58 (1973) 390–400.
[16] G. Allt, J.G. Lawrenson, Is the pial microvessel a good model for blood–brain
barrier studies? Brain Res. Brain Res. Rev. 24 (1997) 67–76.
[17] P. Kivisakk, D.J. Mahad, M.K. Callahan, C. Trebst, B. Tucky, T. Wei, L. Wu, E.S.
Baekkevold, H. Lassmann, S.M. Staugaitis, J.J. Campbell, R.M. Ransohoff, Human
cerebrospinal ﬂuid central memory CD4+ T cells: evidence for trafﬁcking
through choroid plexus and meninges via P-selectin, Proc. Natl. Acad. Sci. U. S. A.
100 (2003) 8389–8394.
[18] S.M. Kerfoot, P. Kubes, Overlapping roles of P-selectin and alpha 4 integrin to
recruit leukocytes to the central nervous system in experimental autoimmune
encephalomyelitis, J. Immunol. 169 (2002) 1000–1006.
[19] L. Battistini, L. Piccio, B. Rossi, S. Bach, S. Galgani, C. Gasperini, L. Ottoboni, D.
Ciabini, M.D. Caramia, G. Bernardi, C. Laudanna, E. Scarpini, R.P. McEver, E.C.
Butcher, G. Borsellino, G. Constantin, CD8+ T cells from patients with acute
multiple sclerosis display selective increase of adhesiveness in brain venules: a
critical role for P-selectin glycoprotein ligand-1, Blood 101 (2003) 4775–4782.
[20] P. Vajkoczy, M. Laschinger, B. Engelhardt, Alpha4-integrin-VCAM-1 binding
mediates G protein-independent capture of encephalitogenic T cell blasts to CNS
white matter microvessels, J. Clin. Invest. 108 (2001) 557–565.
[21] E.E. McCandless, L. Piccio, B.M. Woerner, R.E. Schmidt, J.B. Rubin, A.H. Cross, R.S.
Klein, Pathological expression of CXCL12 at the blood–brain barrier correlates
with severity of multiple sclerosis, Am. J. Pathol. 172 (2008) 799–808.
[22] E.E. McCandless, Q. Wang, B.M. Woerner, J.M. Harper, R.S. Klein, CXCL12 limits
inﬂammation by localizing mononuclear inﬁltrates to the perivascular space
during experimental autoimmune encephalomyelitis, J. Immunol. 177 (2006)
8053–8064.
[23] I. Galea, I. Bechmann, V.H. Perry, What is immune privilege (not)? Trends
Immunol. 28 (2007) 12–18.
[24] M.J. Carson, J.M. Doose, B. Melchior, C.D. Schmid, C.C. Ploix, CNS immune
privilege: hiding in plain sight, Immunol. Rev. 213 (2006) 48–65.
[25] M.K. Matyszak, V.H. Perry, Demyelination in the central nervous system
following a delayed-type hypersensitivity response to bacillus Calmette–Guerin,
Neuroscience 64 (1995) 967–977.
[26] P.G. Stevenson, S. Hawke, D.J. Sloan, C.R. Bangham, The immunogenicity of
intracerebral virus infection depends on anatomical site, J. Virol. 71 (1997)
145–151.
[27] A.P. Byrnes, R.E. MacLaren, H.M. Charlton, Immunological instability of persistent
adenovirus vectors in the brain: peripheral exposure to vector leads to renewed
inﬂammation, reduced gene expression, and demyelination, J. Neurosci. 16
(1996) 3045–3055.
[28] P.R. Lowenstein, Immunology of viral-vector-mediated gene transfer into the
brain: an evolutionary and developmental perspective, Trends Immunol. 23
(2002) 23–30.
[29] M.K. Matyszak, V.H. Perry, A comparison of leucocyte responses to heat-killed
bacillus Calmette–Guerin in different CNS compartments, Neuropathol. Appl.
Neurobiol. 22 (1996) 44–53.
[30] V.H. Perry, A revised view of the central nervous system microenvironment and
major histocompatibility complex class II antigen presentation, J. Neuroimmunol.
90 (1998) 113–121.
228 D.W. Holman et al. / Biochimica et Biophysica Acta 1812 (2011) 220–230[31] D.W. Mason, H.M. Charlton, A.J. Jones, C.B. Lavy, M. Puklavec, S.J. Simmonds, The
fate of allogeneic and xenogeneic neuronal tissue transplanted into the third
ventricle of rodents, Neuroscience 19 (1986) 685–694.
[32] R. Magliozzi, O. Howell, A. Vora, B. Seraﬁni, R. Nicholas, M. Puopolo, R. Reynolds,
F. Aloisi, Meningeal B-cell follicles in secondary progressive multiple sclerosis
associate with early onset of disease and severe cortical pathology, Brain 130
(2007) 1089–1104.
[33] B. Seraﬁni, B. Rosicarelli, R. Magliozzi, E. Stigliano, F. Aloisi, Detection of ectopic
B-cell follicles with germinal centers in the meninges of patients with secondary
progressive multiple sclerosis, Brain Pathol. 14 (2004) 164–174.
[34] P. Kivisakk, J. Imitola, S. Rasmussen, W. Elyaman, B. Zhu, R.M. Ransohoff, S.J.
Khoury, Localizing central nervous system immune surveillance: meningeal
antigen-presenting cells activate T cells during experimental autoimmune
encephalomyelitis, Ann. Neurol. 65 (2009) 457–469.
[35] H.L. Goldsmith, S. Spain, Margination of leukocytes in blood ﬂow through small
tubes, Microvasc. Res. 27 (1984) 204–222.
[36] K. Ley, Molecular mechanisms of leukocyte recruitment in the inﬂammatory
process, Cardiovasc. Res. 32 (1996) 733–742.
[37] G.W. Schmid-Schonbein, S. Usami, R. Skalak, S. Chien, The interaction of
leukocytes and erythrocytes in capillary and postcapillary vessels, Microvasc.
Res. 19 (1980) 45–70.
[38] U. Nobis, A.R. Pries, G.R. Cokelet, P. Gaehtgens, Radial distribution of white cells
during blood ﬂow in small tubes, Microvasc. Res. 29 (1985) 295–304.
[39] K. Ley, C. Laudanna, M.I. Cybulsky, S. Nourshargh, Getting to the site of
inﬂammation: the leukocyte adhesion cascade updated, Nat. Rev. Immunol. 7
(2007) 678–689.
[40] B. Johnston, E.C. Butcher, Chemokines in rapid leukocyte adhesion triggering and
migration, Semin. Immunol. 14 (2002) 83–92.
[41] R. Alon, S. Feigelson, From rolling to arrest on blood vessels: leukocyte tap
dancing on endothelial integrin ligands and chemokines at sub-second contacts,
Semin. Immunol. 14 (2002) 93–104.
[42] G. Cinamon, V. Grabovsky, E. Winter, S. Franitza, S. Feigelson, R. Shamri, O. Dwir,
R. Alon, Novel chemokine functions in lymphocyte migration through vascular
endothelium under shear ﬂow, J. Leukoc. Biol. 69 (2001) 860–866.
[43] P. Adamson, B. Wilbourn, S. Etienne-Manneville, V. Calder, E. Beraud, G. Milligan,
P.O. Couraud, J. Greenwood, Lymphocyte trafﬁcking through the blood–brain
barrier is dependent on endothelial cell heterotrimeric G-protein signaling,
FASEB J. 16 (2002) 1185–1194.
[44] A.E. Proudfoot, The biological relevance of chemokine–proteoglycan interac-
tions, Biochem. Soc. Trans. 34 (2006) 422–426.
[45] C.R. Parish, The role of heparan sulphate in inﬂammation, Nat. Rev. Immunol. 6
(2006) 633–643.
[46] C.V. Carman, T.A. Springer, Trans-cellular migration: cell–cell contacts get
intimate, Curr. Opin. Cell Biol. 20 (2008) 533–540.
[47] D. Vestweber, Adhesion and signaling molecules controlling the transmigration
of leukocytes through endothelium, Immunol. Rev. 218 (2007) 178–196.
[48] F. Liao, J. Ali, T. Greene, W.A. Muller, Soluble domain 1 of platelet-endothelial cell
adhesion molecule (PECAM) is sufﬁcient to block transendothelial migration in
vitro and in vivo, J. Exp. Med. 185 (1997) 1349–1357.
[49] F. Liao, H.K. Huynh, A. Eiroa, T. Greene, E. Polizzi, W.A. Muller, Migration of
monocytes across endothelium and passage through extracellularmatrix involve
separate molecular domains of PECAM-1, J. Exp. Med. 182 (1995) 1337–1343.
[50] G.S. Duncan, D.P. Andrew, H. Takimoto, S.A. Kaufman, H. Yoshida, J. Spellberg, J.
Luis de la Pompa, A. Elia, A. Wakeham, B. Karan-Tamir, W.A. Muller, G. Senaldi,
M.M. Zukowski, T.W. Mak, Genetic evidence for functional redundancy of
Platelet/Endothelial cell adhesion molecule-1 (PECAM-1): CD31-deﬁcient mice
reveal PECAM-1-dependent and PECAM-1-independent functions, J. Immunol.
162 (1999) 3022–3030.
[51] M.W.Wakelin, M.J. Sanz, A. Dewar, S.M. Albelda, S.W. Larkin, N. Boughton-Smith,
T.J. Williams, S. Nourshargh, An anti-platelet-endothelial cell adhesion mole-
cule-1 antibody inhibits leukocyte extravasation from mesenteric microvessels
in vivo by blocking the passage through the basement membrane, J. Exp. Med.
184 (1996) 229–239.
[52] A.R. Schenkel, Z. Mamdouh, X. Chen, R.M. Liebman, W.A. Muller, CD99 plays a
major role in the migration of monocytes through endothelial junctions, Nat.
Immunol. 3 (2002) 143–150.
[53] G. Bixel, S. Kloep, S. Butz, B. Petri, B. Engelhardt, D. Vestweber, Mouse CD99
participates in T-cell recruitment into inﬂamed skin, Blood 104 (2004) 3205–3213.
[54] B. Engelhardt, H. Wolburg, Mini-review: Transendothelial migration of leuko-
cytes: through the front door or around the side of the house? Eur. J. Immunol.
34 (2004) 2955–2963.
[55] C.S. Raine, B. Cannella, A.M. Duijvestijn, A.H. Cross, Homing to central nervous
system vasculature by antigen-speciﬁc lymphocytes. II. Lymphocyte/endothelial
cell adhesion during the initial stages of autoimmune demyelination, Lab. Invest.
63 (1990) 476–489.
[56] H. Wolburg, K. Wolburg-Buchholz, B. Engelhardt, Diapedesis of mononuclear
cells across cerebral venules during experimental autoimmune encephalomy-
elitis leaves tight junctions intact, Acta Neuropathol. 109 (2005) 181–190.
[57] U. Kniesel, W. Risau, H. Wolburg, Development of blood–brain barrier tight
junctions in the rat cortex, Brain Res. Dev. Brain Res. 96 (1996) 229–240.
[58] T. Owens, I. Bechmann, B. Engelhardt, Perivascular spaces and the two steps to
neuroinﬂammation, J. Neuropathol. Exp. Neurol. 67 (2008) 1113–1121.
[59] I. Bartholomaus, N. Kawakami, F. Odoardi, C. Schlager, D. Miljkovic, J.W. Ellwart,
W.E. Klinkert, C. Flugel-Koch, T.B. Issekutz, H. Wekerle, A. Flugel, Effector T cell
interactions with meningeal vascular structures in nascent autoimmune CNS
lesions, Nature 462 (2009) 94–98.[60] R.M. Ransohoff, Immunology: in the beginning, Nature 462 (2009) 41–42.
[61] C.O. Zachariae, Chemotactic cytokines and inﬂammation. Biological properties of
the lymphocyte and monocyte chemotactic factors ELCF, MCAF and IL-8, Acta
Derm. Venereol. Suppl. (Stockh.) 181 (1993) 1–37.
[62] A. Rot, Neutrophil attractant/activation protein-1 (interleukin-8) induces in
vitro neutrophil migration by haptotactic mechanism, Eur. J. Immunol. 23 (1993)
303–306.
[63] Z. Johnson, M.H. Kosco-Vilbois, S. Herren, R. Cirillo, V. Muzio, P. Zaratin, M.
Carbonatto, M. Mack, A. Smailbegovic, M. Rose, R. Lever, C. Page, T.N. Wells, A.E.
Proudfoot, Interference with heparin binding and oligomerization creates a
novel anti-inﬂammatory strategy targeting the chemokine system, J. Immunol.
173 (2004) 5776–5785.
[64] A. Peled, V. Grabovsky, L. Habler, J. Sandbank, F. Arenzana-Seisdedos, I. Petit, H.
Ben-Hur, T. Lapidot, R. Alon, The chemokine SDF-1 stimulates integrin-mediated
arrest of CD34(+) cells on vascular endothelium under shear ﬂow, J. Clin. Invest.
104 (1999) 1199–1211.
[65] G. Cinamon, V. Shinder, R. Alon, Shear forces promote lymphocyte migration
across vascular endothelium bearing apical chemokines, Nat. Immunol. 2 (2001)
515–522.
[66] T.H. Schreiber, V. Shinder, D.W. Cain, R. Alon, R. Sackstein, Shear ﬂow-dependent
integration of apical and subendothelial chemokines in T-cell transmigration:
implications for locomotion and the multistep paradigm, Blood 109 (2007)
1381–1386.
[67] T.M. Handel, Z. Johnson, S.E. Crown, E.K. Lau, A.E. Proudfoot, Regulation of
protein function by glycosaminoglycans—as exempliﬁed by chemokines, Annu.
Rev. Biochem. 74 (2005) 385–410.
[68] D. Spillmann, D. Witt, U. Lindahl, Deﬁning the interleukin-8-binding domain of
heparan sulfate, J. Biol. Chem. 273 (1998) 15487–15493.
[69] A. Amara, O. Lorthioir, A. Valenzuela, A. Magerus, M. Thelen, M. Montes, J.L.
Virelizier, M. Delepierre, F. Baleux, H. Lortat-Jacob, F. Arenzana-Seisdedos,
Stromal cell-derived factor-1alpha associates with heparan sulfates through the
ﬁrst beta-strand of the chemokine, J. Biol. Chem. 274 (1999) 23916–23925.
[70] L. Martin, C. Blanpain, P. Garnier, V. Wittamer, M. Parmentier, C. Vita, Structural
and functional analysis of the RANTES-glycosaminoglycans interactions, Bio-
chemistry 40 (2001) 6303–6318.
[71] A.J. Hoogewerf, G.S. Kuschert, A.E. Proudfoot, F. Borlat, I. Clark-Lewis, C.A. Power,
T.N. Wells, Glycosaminoglycans mediate cell surface oligomerization of
chemokines, Biochemistry 36 (1997) 13570–13578.
[72] H. Ranjbaran, Y. Wang, T.D. Manes, A.O. Yakimov, S. Akhtar, M.S. Kluger, J.S.
Pober, G. Tellides, Heparin displaces interferon-gamma-inducible chemokines
(IP-10, I-TAC, and Mig) sequestered in the vasculature and inhibits the
transendothelial migration and arterial recruitment of T cells, Circulation 114
(2006) 1293–1300.
[73] A.E. Proudfoot, T.M. Handel, Z. Johnson, E.K. Lau, P. LiWang, I. Clark-Lewis, F.
Borlat, T.N. Wells, M.H. Kosco-Vilbois, Glycosaminoglycan binding and oligo-
merization are essential for the in vivo activity of certain chemokines, Proc. Natl.
Acad. Sci. U. S. A. 100 (2003) 1885–1890.
[74] S. Ali, H. Robertson, J.H. Wain, J.D. Isaacs, G. Malik, J.A. Kirby, A non-
glycosaminoglycan-binding variant of CC chemokine ligand 7 (monocyte
chemoattractant protein-3) antagonizes chemokine-mediated inﬂammation, J.
Immunol. 175 (2005) 1257–1266.
[75] F.C. Peterson, E.S. Elgin, T.J. Nelson, F. Zhang, T.J. Hoeger, R.J. Linhardt, B.F. Volkman,
Identiﬁcation and characterization of a glycosaminoglycan recognition element of
the C chemokine lymphotactin, J. Biol. Chem. 279 (2004) 12598–12604.
[76] Z. Johnson, A.E. Proudfoot, T.M. Handel, Interaction of chemokines and glycosami-
noglycans: a new twist in the regulation of chemokine functionwith opportunities
for therapeutic intervention, Cytokine Growth Factor Rev. 16 (2005) 625–636.
[77] W.W. Agace, Tissue-tropic effector T cells: generation and targeting opportuni-
ties, Nat. Rev. Immunol. 6 (2006) 682–692.
[78] L. Wang, M. Fuster, P. Sriramarao, J.D. Esko, Endothelial heparan sulfate
deﬁciency impairs L-selectin- and chemokine-mediated neutrophil trafﬁcking
during inﬂammatory responses, Nat. Immunol. 6 (2005) 902–910.
[79] S.S. Shaik, T.D. Soltau, G. Chaturvedi, B. Totapally, J.S. Hagood, W.W. Andrews, M.
Athar, N.N. Voitenok, C.R. Killingsworth, R.P. Patel, M.B. Fallon, A. Maheshwari,
Low intensity shear stress increases endothelial ELR+ CXC chemokine
production via a focal adhesion kinase-p38{beta} MAPK-NF-{kappa}B pathway,
J. Biol. Chem. 284 (2009) 5945–5955.
[80] J. Hol, A.M. Kuchler, F.E. Johansen, B. Dalhus, G. Haraldsen, I. Oynebraten,
Molecular requirements for sorting of the chemokine IL-8/CXCL8 to endothelial
Weibel–Palade bodies, J. Biol. Chem. 284 (2009) 23532–23539.
[81] J.O. Utgaard, F.L. Jahnsen, A. Bakka, P. Brandtzaeg, G. Haraldsen, Rapid secretion
of prestored interleukin 8 from Weibel–Palade bodies of microvascular
endothelial cells, J. Exp. Med. 188 (1998) 1751–1756.
[82] B. Wolff, A.R. Burns, J. Middleton, A. Rot, Endothelial cell “memory” of
inﬂammatory stimulation: human venular endothelial cells store interleukin
8 in Weibel–Palade bodies, J. Exp. Med. 188 (1998) 1757–1762.
[83] F.J. Barkalow, M.J. Goodman, M.E. Gerritsen, T.N. Mayadas, Brain endothelium
lack one of two pathways of P-selectin-mediated neutrophil adhesion, Blood 88
(1996) 4585–4593.
[84] F.J. Barkalow, M.J. Goodman, T.N. Mayadas, Cultured murine cerebral microvas-
cular endothelial cells contain von Willebrand factor-positive Weibel–Palade
bodies and support rapid cytokine-induced neutrophil adhesion, Microcircula-
tion 3 (1996) 19–28.
[85] A.E. Cardona, M. Li, L. Liu, C. Savarin, R.M. Ransohoff, Chemokines in and out of
the central nervous system: much more than chemotaxis and inﬂammation, J.
Leukoc. Biol. 84 (2008) 587–594.
229D.W. Holman et al. / Biochimica et Biophysica Acta 1812 (2011) 220–230[86] U. Panzer, O.M. Steinmetz, R.R. Reinking, T.N. Meyer, S. Fehr, A. Schneider, G.
Zahner, G. Wolf, U. Helmchen, P. Schaerli, R.A. Stahl, F. Thaiss, Compartment-
speciﬁc expression and function of the chemokine IP-10/CXCL10 in a model of
renal endothelial microvascular injury, J. Am. Soc. Nephrol. 17 (2006) 454–464.
[87] B.C. Kieseier, M. Tani, D. Mahad, N. Oka, T. Ho, N. Woodroofe, J.W. Grifﬁn, K.V.
Toyka, R.M. Ransohoff, H.P. Hartung, Chemokines and chemokine receptors in
inﬂammatory demyelinating neuropathies: a central role for IP-10, Brain 125
(2002) 823–834.
[88] J. Reutershan, M.A. Morris, T.L. Burcin, D.F. Smith, D. Chang, M.S. Saprito, K. Ley,
Critical role of endothelial CXCR2 in LPS-induced neutrophil migration into the
lung, J. Clin. Invest. 116 (2006) 695–702.
[89] J. Reutershan, B. Harry, D. Chang, G.J. Bagby, K. Ley, DARC on RBC limits lung
injury by balancing compartmental distribution of CXC chemokines, Eur. J.
Immunol. 39 (2009) 1597–1607.
[90] C.L. Tsou, C.A. Haskell, I.F. Charo, Tumor necrosis factor-alpha-converting enzyme
mediates the inducible cleavage of fractalkine, J. Biol. Chem. 276 (2001)
44622–44626.
[91] D.D. Patel, W. Koopmann, T. Imai, L.P. Whichard, O. Yoshie, M.S. Krangel,
Chemokines have diverse abilities to form solid phase gradients, Clin. Immunol.
99 (2001) 43–52.
[92] A.M. Fong, L.A. Robinson, D.A. Steeber, T.F. Tedder, O. Yoshie, T. Imai, D.D. Patel,
Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture,
ﬁrm adhesion, and activation under physiologic ﬂow, J. Exp. Med. 188 (1998)
1413–1419.
[93] H. Umehara, T. Imai, Role of fractalkine in leukocyte adhesion and migration and
in vascular injury, Drug News Perspect. 14 (2001) 460–464.
[94] J.K. Harrison, Y. Jiang, S. Chen, Y. Xia, D. Maciejewski, R.K. McNamara, W.J. Streit,
M.N. Salafranca, S. Adhikari, D.A. Thompson, P. Botti, K.B. Bacon, L. Feng, Role
for neuronally derived fractalkine in mediating interactions between neurons
and CX3CR1-expressing microglia, Proc. Natl. Acad. Sci. U. S. A. 95 (1998)
10896–10901.
[95] D. Sunnemark, S. Eltayeb, M. Nilsson, E. Wallstrom, H. Lassmann, T. Olsson, A.L.
Berg, A. Ericsson-Dahlstrand, CX3CL1 (fractalkine) and CX3CR1 expression in
myelin oligodendrocyte glycoprotein-induced experimental autoimmune en-
cephalomyelitis: kinetics and cellular origin, J. Neuroinﬂammation 2 (2005) 17.
[96] D. Huang, F.D. Shi, S. Jung, G.C. Pien, J. Wang, T.P. Salazar-Mather, T.T. He, J.T.
Weaver, H.G. Ljunggren, C.A. Biron, D.R. Littman, R.M. Ransohoff, The neuronal
chemokine CX3CL1/fractalkine selectively recruits NK cells that modify
experimental autoimmune encephalomyelitis within the central nervous
system, FASEB J. 20 (2006) 896–905.
[97] A.V. Andjelkovic, D.D. Spencer, J.S. Pachter, Visualization of chemokine binding
sites on human brain microvessels, J. Cell Biol. 145 (1999) 403–412.
[98] O.B. Dimitrijevic, S.M. Stamatovic, R.F. Keep, A.V. Andjelkovic, Effects of the
chemokine CCL2 on blood–brain barrier permeability during ischemia–reperfu-
sion injury, J. Cereb. Blood Flow Metab. 26 (2006) 797–810.
[99] S.M. Stamatovic, R.F. Keep, S.L. Kunkel, A.V. Andjelkovic, Potential role of MCP-1
in endothelial cell tight junction ‘opening’: signaling via Rho and Rho kinase,
J. Cell Sci. 116 (2003) 4615–4628.
[100] J. Quandt, K. Dorovini-Zis, The beta chemokines CCL4 and CCL5 enhance
adhesion of speciﬁc CD4+ T cell subsets to human brain endothelial cells,
J. Neuropathol. Exp. Neurol. 63 (2004) 350–362.
[101] A. Szczucinski, J. Losy, Chemokines and chemokine receptors inmultiple sclerosis.
Potential targets for new therapies, Acta Neurol. Scand. 115 (2007) 137–146.
[102] L. Izikson, R.S. Klein, I.F. Charo, H.L. Weiner, A.D. Luster, Resistance to
experimental autoimmune encephalomyelitis in mice lacking the CC chemokine
receptor (CCR)2, J. Exp. Med. 192 (2000) 1075–1080.
[103] L. Izikson, R.S. Klein, A.D. Luster, H.L. Weiner, Targeting monocyte recruitment in
CNS autoimmune disease, Clin. Immunol. 103 (2002) 125–131.
[104] B.T. Fife, G.B. Huffnagle, W.A. Kuziel, W.J. Karpus, CC chemokine receptor 2 is
critical for induction of experimental autoimmune encephalomyelitis, J. Exp.
Med. 192 (2000) 899–905.
[105] B.T. Fife, M.C. Paniagua, N.W. Lukacs, S.L. Kunkel, W.J. Karpus, Selective CC
chemokine receptor expression by central nervous system-inﬁltrating enceph-
alitogenic T cells during experimental autoimmune encephalomyelitis,
J. Neurosci. Res. 66 (2001) 705–714.
[106] D. Mahad, M.K. Callahan, K.A. Williams, E.E. Ubogu, P. Kivisakk, B. Tucky, G. Kidd,
G.A. Kingsbury, A. Chang, R.J. Fox, M. Mack, M.B. Sniderman, R. Ravid, S.M.
Staugaitis, M.F. Stins, R.M. Ransohoff, Modulating CCR2 and CCL2 at the blood–
brain barrier: relevance for multiple sclerosis pathogenesis, Brain 129 (2006)
212–223.
[107] D.J.Mahad, R.M. Ransohoff, The role ofMCP-1 (CCL2) and CCR2 inmultiple sclerosis
and experimental autoimmune encephalomyelitis (EAE), Semin. Immunol. 15
(2003) 23–32.
[108] T.L. Sorensen, R.M. Ransohoff, R.M. Strieter, F. Sellebjerg, Chemokine CCL2 and
chemokine receptor CCR2 in early active multiple sclerosis, Eur. J. Neurol. 11
(2004) 445–449.
[109] S. Gaupp, D. Pitt, W.A. Kuziel, B. Cannella, C.S. Raine, Experimental autoimmune
encephalomyelitis (EAE) in CCR2(−/−) mice: susceptibility in multiple strains,
Am. J. Pathol. 162 (2003) 139–150.
[110] D.R. Huang, J. Wang, P. Kivisakk, B.J. Rollins, R.M. Ransohoff, Absence of monocyte
chemoattractantprotein 1 inmice leads todecreased localmacrophage recruitment
and antigen-speciﬁc T helper cell type 1 immune response in experimental
autoimmune encephalomyelitis, J. Exp. Med. 193 (2001) 713–726.
[111] B.H. Bennetts, S.M. Teutsch, M.M. Buhler, R.N. Heard, G.J. Stewart, The CCR5
deletion mutation fails to protect against multiple sclerosis, Hum. Immunol. 58
(1997) 52–59.[112] E.H. Tran, W.A. Kuziel, T. Owens, Induction of experimental autoimmune
encephalomyelitis in C57BL/6 mice deﬁcient in either the chemokine macro-
phage inﬂammatory protein-1alpha or its CCR5 receptor, Eur. J. Immunol. 30
(2000) 1410–1415.
[113] M.F. Bachmann, M. Kopf, B.J. Marsland, Chemokines: more than just road signs,
Nat. Rev. Immunol. 6 (2006) 159–164.
[114] S.K. Bromley, T.R. Mempel, A.D. Luster, Orchestrating the orchestrators:
chemokines in control of T cell trafﬁc, Nat. Immunol. 9 (2008) 970–980.
[115] C. Alt, M. Laschinger, B. Engelhardt, Functional expression of the lymphoid
chemokines CCL19 (ELC) and CCL 21 (SLC) at the blood–brain barrier suggests
their involvement in G-protein-dependent lymphocyte recruitment into the
central nervous system during experimental autoimmune encephalomyelitis,
Eur. J. Immunol. 32 (2002) 2133–2144.
[116] S. Columba-Cabezas, B. Seraﬁni, E. Ambrosini, F. Aloisi, Lymphoid chemokines
CCL19 and CCL21 are expressed in the central nervous system during
experimental autoimmune encephalomyelitis: implications for the maintenance
of chronic neuroinﬂammation, Brain Pathol. 13 (2003) 38–51.
[117] S.C. Chen, M.W. Leach, Y. Chen, X.Y. Cai, L. Sullivan, M. Wiekowski, B.J. Dovey-
Hartman, A. Zlotnik, S.A. Lira, Central nervous system inﬂammation and
neurological disease in transgenic mice expressing the CC chemokine CCL21 in
oligodendrocytes, J. Immunol. 168 (2002) 1009–1017.
[118] K. Biber, A. Sauter, N. Brouwer, S.C. Copray, H.W. Boddeke, Ischemia-induced
neuronal expression of the microglia attracting chemokine Secondary Lym-
phoid-tissue Chemokine (SLC), Glia 34 (2001) 121–133.
[119] I.M. Dijkstra, S. Hulshof, P. van der Valk, H.W. Boddeke, K. Biber, Cutting edge:
activity of human adult microglia in response to CC chemokine ligand 21,
J. Immunol. 172 (2004) 2744–2747.
[120] A. Rappert, K. Biber, C. Nolte, M. Lipp, A. Schubel, B. Lu, N.P. Gerard, C. Gerard, H.
W. Boddeke, H. Kettenmann, Secondary lymphoid tissue chemokine (CCL21)
activates CXCR3 to trigger a Cl− current and chemotaxis in murine microglia,
J. Immunol. 168 (2002) 3221–3226.
[121] H.R. Weering, A.P. Jong, A.H. Haas, K.P. Biber, H.W. Boddeke, CCL21-induced
calcium transients and proliferation in primary mouse astrocytes: CXCR3-
dependent and independent responses, Brain Behav. Immun. 24 (2009)
768–775.
[122] P. Kivisakk, D.J. Mahad, M.K. Callahan, K. Sikora, C. Trebst, B. Tucky, J. Wujek, R.
Ravid, S.M. Staugaitis, H. Lassmann, R.M. Ransohoff, Expression of CCR7 in
multiple sclerosis: implications for CNS immunity, Ann. Neurol. 55 (2004)
627–638.
[123] S. Buonamici, T. Trimarchi, M.G. Ruocco, L. Reavie, S. Cathelin, B.G. Mar, A.
Klinakis, Y. Lukyanov, J.C. Tseng, F. Sen, E. Gehrie, M. Li, E. Newcomb, J. Zavadil, D.
Meruelo, M. Lipp, S. Ibrahim, A. Efstratiadis, D. Zagzag, J.S. Bromberg, M.L. Dustin,
I. Aifantis, CCR7 signalling as an essential regulator of CNS inﬁltration in T-cell
leukaemia, Nature 459 (2009) 1000–1004.
[124] A. Reboldi, C. Coisne, D. Baumjohann, F. Benvenuto, D. Bottinelli, S. Lira, A. Uccelli,
A. Lanzavecchia, B. Engelhardt, F. Sallusto, C–C chemokine receptor 6-regulated
entry of TH-17 cells into the CNS through the choroid plexus is required for the
initiation of EAE, Nat. Immunol. 10 (2009) 514–523.
[125] M. Krumbholz, D. Theil, F. Steinmeyer, S. Cepok, B. Hemmer, M. Hofbauer, C.
Farina, T. Derfuss, A. Junker, T. Arzberger, I. Sinicina, C. Hartle, J. Newcombe, R.
Hohlfeld, E. Meinl, CCL19 is constitutively expressed in the CNS, up-regulated in
neuroinﬂammation, active and also inactive multiple sclerosis lesions,
J. Neuroimmunol. 190 (2007) 72–79.
[126] C.C. Bleul, R.C. Fuhlbrigge, J.M. Casasnovas, A. Aiuti, T.A. Springer, A highly
efﬁcacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1),
J. Exp. Med. 184 (1996) 1101–1109.
[127] R.K. Stumm, J. Rummel, V. Junker, C. Culmsee, M. Pfeiffer, J. Krieglstein, V. Hollt, S.
Schulz, A dual role for the SDF-1/CXCR4 chemokine receptor system in adult
brain: isoform-selective regulation of SDF-1 expression modulates CXCR4-
dependent neuronal plasticity and cerebral leukocyte recruitment after focal
ischemia, J. Neurosci. 22 (2002) 5865–5878.
[128] M. Li, R.M. Ransohoff, Multiple roles of chemokine CXCL12 in the central nervous
system: a migration from immunology to neurobiology, Prog. Neurobiol. 84
(2008) 116–131.
[129] R.S. Klein, J.B. Rubin, Immune and nervous system CXCL12 and CXCR4: parallel
roles in patterning and plasticity, Trends Immunol. 25 (2004) 306–314.
[130] P. van der Meer, A.M. Ulrich, F. Gonzalez-Scarano, E. Lavi, Immunohistochemical
analysis of CCR2, CCR3, CCR5, and CXCR4 in the human brain: potential
mechanisms for HIV dementia, Exp. Mol. Pathol. 69 (2000) 192–201.
[131] E.E. Jazin, S. Soderstrom, T. Ebendal, D. Larhammar, Embryonic expression of
the mRNA for the rat homologue of the fusin/CXCR-4 HIV-1 co-receptor,
J. Neuroimmunol. 79 (1997) 148–154.
[132] K.E. McGrath, A.D. Koniski, K.M. Maltby, J.K. McGann, J. Palis, Embryonic
expression and function of the chemokine SDF-1 and its receptor, CXCR4, Dev.
Biol. 213 (1999) 442–456.
[133] M. Krumbholz, D. Theil, S. Cepok, B. Hemmer, P. Kivisakk, R.M. Ransohoff, M.
Hofbauer, C. Farina, T. Derfuss, C. Hartle, J. Newcombe, R. Hohlfeld, E. Meinl,
Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is
differentially linked to CNS immune cell recruitment, Brain 129 (2006) 200–211.
[134] E.E. McCandless, B. Zhang, M.S. Diamond, R.S. Klein, CXCR4 antagonism increases
T cell trafﬁcking in the central nervous system and improves survival fromWest
Nile virus encephalitis, Proc. Natl. Acad. Sci. U.S.A 105 (2008) 11270–11275.
[135] E.E. McCandless, M. Budde, J.R. Lees, D. Dorsey, E. Lyng, R.S. Klein, IL-1R signaling
within the central nervous system regulates CXCL12 expression at the blood–
brain barrier and disease severity during experimental autoimmune encepha-
lomyelitis, J. Immunol. 183 (2009) 613–620.
230 D.W. Holman et al. / Biochimica et Biophysica Acta 1812 (2011) 220–230[136] K. Balabanian, B. Lagane, S. Infantino, K.Y. Chow, J. Harriague, B. Moepps, F.
Arenzana-Seisdedos, M. Thelen, F. Bachelerie, The chemokine SDF-1/CXCL12
binds to and signals through the orphan receptor RDC1 in T lymphocytes, J. Biol.
Chem. 280 (2005) 35760–35766.
[137] J.M. Burns, B.C. Summers, Y. Wang, A. Melikian, R. Berahovich, Z. Miao, M.E.
Penfold, M.J. Sunshine, D.R. Littman, C.J. Kuo, K.Wei, B.E. McMaster, K. Wright, M.
C. Howard, T.J. Schall, A novel chemokine receptor for SDF-1 and I-TAC involved
in cell survival, cell adhesion, and tumor development, J. Exp. Med. 203 (2006)
2201–2213.
[138] B. Mazzinghi, E. Ronconi, E. Lazzeri, C. Sagrinati, L. Ballerini, M.L. Angelotti, E.
Parente, R. Mancina, G.S. Netti, F. Becherucci, M. Gacci, M. Carini, L. Gesualdo, M.
Rotondi, E. Maggi, L. Lasagni, M. Serio, S. Romagnani, P. Romagnani, Essential but
differential role for CXCR4 and CXCR7 in the therapeutic homing of human renal
progenitor cells, J. Exp. Med. 205 (2008) 479–490.
[139] F. Sierro, C. Biben, L. Martinez-Munoz, M. Mellado, R.M. Ransohoff, M. Li, B.
Woehl, H. Leung, J. Groom, M. Batten, R.P. Harvey, A.C. Martinez, C.R. Mackay, F.
Mackay, Disrupted cardiac development but normal hematopoiesis in mice
deﬁcient in the second CXCL12/SDF-1 receptor, CXCR7, Proc. Natl. Acad. Sci. U. S.
A. 104 (2007) 14759–14764.
[140] J. Wang, Y. Shiozawa, J. Wang, Y. Wang, Y. Jung, K.J. Pienta, R. Mehra, R. Loberg, R.
S. Taichman, The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1
in prostate cancer, J. Biol. Chem. 283 (2008) 4283–4294.
[141] P. Proost, A. Mortier, T. Loos, J. Vandercappellen, M. Gouwy, I. Ronsse, E.
Schutyser, W. Put, M. Parmentier, S. Struyf, J. Van Damme, Proteolytic processing
of CXCL11 by CD13/aminopeptidase N impairs CXCR3 and CXCR7 binding and
signaling and reduces lymphocyte and endothelial cell migration, Blood 110
(2007) 37–44.
[142] D. Yoshida, R. Nomura, A. Teramoto, Signaling pathway mediated by CXCR7, an
alternative chemokine receptor for stromal-cell derived factor-1alpha, in AtT20
mouse ACTH-secreting pituitary adenoma cells, J. Neuroendocrinol. 21 (2009)
481–488.
[142] T.N. Hartmann, V. Grabovsky, R. Pasvolsky, Z. Shulman, E.C. Buss, A. Spiegel, A.
Nagler, T. Lapidot, M. Thelen, R. Alon, A crosstalk between intracellular CXCR7
and CXCR4 involved in rapid CXCL12-triggered integrin activation but not in
chemokine-triggered motility of human T lymphocytes and CD34+ cells, J.
Leukoc. Biol. 84 (2008) 1130–1140.
[144] B. Boldajipour, H. Mahabaleshwar, E. Kardash, M. Reichman-Fried, H. Blaser, S.
Minina, D. Wilson, Q. Xu, E. Raz, Control of chemokine-guided cell migration by
ligand sequestration, Cell 132 (2008) 463–473.
[145] H. Mahabaleshwar, B. Boldajipour, E. Raz, Killing the messenger: the role of CXCR7
in regulating primordial germ cell migration, Cell Adh. Migr. 2 (2008) 69–70.
[146] B. Schonemeier, A. Kolodziej, S. Schulz, S. Jacobs, V. Hoellt, R. Stumm, Regional
and cellular localization of the CXCl12/SDF-1 chemokine receptor CXCR7 in the
developing and adult rat brain, J. Comp. Neurol. 510 (2008) 207–220.
[147] B. Schonemeier, S. Schulz, V. Hoellt, R. Stumm, Enhanced expression of the
CXCl12/SDF-1 chemokine receptor CXCR7 after cerebral ischemia in the rat
brain, J. Neuroimmunol. 198 (2008) 39–45.
[148] Z. Miao, K.E. Luker, B.C. Summers, R. Berahovich, M.S. Bhojani, A. Rehemtulla, C.G.
Kleer, J.J. Essner, A. Nasevicius, G.D. Luker, M.C. Howard, T.J. Schall, CXCR7 (RDC1)
promotes breast and lung tumor growth in vivo and is expressed on tumor-
associated vasculature, Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 15735–15740.
[149] B.A. Zabel, Y. Wang, S. Lewen, R.D. Berahovich, M.E. Penfold, P. Zhang, J. Powers,
B.C. Summers, Z. Miao, B. Zhao, A. Jalili, A. Janowska-Wieczorek, J.C. Jaen, T.J.
Schall, Elucidation of CXCR7-mediated signaling events and inhibition of CXCR4-mediated tumor cell transendothelial migration by CXCR7 ligands, J. Immunol.
183 (2009) 3204–3211.
[150] A.A. Maghazachi, G protein-coupled receptors in natural killer cells, J. Leukoc.
Biol. 74 (2003) 16–24.
[151] A. Dagkalis, C. Wallace, B. Hing, J. Liversidge, I.J. Crane, CX3CR1-deﬁciency is
associated with increased severity of disease in experimental autoimmune
uveitis, Immunology 128 (2009) 25–33.
[152] E.H. Tran, E.N. Prince, T. Owens, IFN-gamma shapes immune invasion of the
central nervous system via regulation of chemokines, J. Immunol. 164 (2000)
2759–2768.
[153] T. Carlson, M. Kroenke, P. Rao, T.E. Lane, B. Segal, The Th17-ELR+ CXC chemokine
pathway is essential for the development of central nervous system autoim-
mune disease, J. Exp. Med. 205 (2008) 811–823.
[154] S.S. Shaftel, T.J. Carlson, J.A. Olschowka, S. Kyrkanides, S.B. Matousek, M.K.
O'Banion, Chronic interleukin-1beta expression in mouse brain leads to
leukocyte inﬁltration and neutrophil-independent blood brain barrier perme-
ability without overt neurodegeneration, J. Neurosci. 27 (2007) 9301–9309.
[155] U.K. Hanisch, Microglia as a source and target of cytokines, Glia 40 (2002)
140–155.
[156] G.W. Kreutzberg, Microglia: a sensor for pathological events in the CNS, Trends
Neurosci. 19 (1996) 312–318.
[157] F. Gonzalez-Scarano, G. Baltuch, Microglia as mediators of inﬂammatory and
degenerative diseases, Annu. Rev. Neurosci. 22 (1999) 219–240.
[158] Y.Q. Li, P. Chen, V. Jain, R.M. Reilly, C.S. Wong, Early radiation-induced
endothelial cell loss and blood–spinal cord barrier breakdown in the rat spinal
cord, Radiat. Res. 161 (2004) 143–152.
[159] M. Diserbo, A. Agin, I. Lamproglou, J. Mauris, F. Staali, E. Multon, C. Amourette,
Blood–brain barrier permeability after gamma whole-body irradiation: an in
vivo microdialysis study, Can. J. Physiol. Pharmacol. 80 (2002) 670–678.
[160] B. Ajami, J.L. Bennett, C. Krieger, W. Tetzlaff, F.M. Rossi, Local self-renewal can
sustain CNS microglia maintenance and function throughout adult life, Nat.
Neurosci. 10 (2007) 1538–1543.
[161] D.C. Hess, T. Abe, W.D. Hill, A.M. Studdard, J. Carothers, M. Masuya, P.A. Fleming,
C.J. Drake, M. Ogawa, Hematopoietic origin of microglial and perivascular cells in
brain, Exp. Neurol. 186 (2004) 134–144.
[162] A.R. Simard, S. Rivest, Bone marrow stem cells have the ability to populate the
entire central nervous system into fully differentiated parenchymal microglia,
FASEB J. 18 (2004) 998–1000.
[163] J. Priller, A. Flugel, T. Wehner, M. Boentert, C.A. Haas, M. Prinz, F. Fernandez-Klett,
K. Prass, I. Bechmann, B.A. de Boer, M. Frotscher, G.W. Kreutzberg, D.A. Persons,
U. Dirnagl, Targeting gene-modiﬁed hematopoietic cells to the central nervous
system: use of green ﬂuorescent protein uncovers microglial engraftment, Nat.
Med. 7 (2001) 1356–1361.
[164] D.W. Kennedy, J.L. Abkowitz, Kinetics of central nervous system microglial and
macrophage engraftment: analysis using a transgenic bone marrow transplan-
tation model, Blood 90 (1997) 986–993.
[165] A. Flugel, M. Bradl, G.W. Kreutzberg, M.B. Graeber, Transformation of donor-
derived bone marrow precursors into host microglia during autoimmune CNS
inﬂammation and during the retrograde response to axotomy, J. Neurosci. Res.
66 (2001) 74–82.
[166] A. Mildner, H. Schmidt, M. Nitsche, D. Merkler, U.K. Hanisch, M. Mack, M.
Heikenwalder, W. Bruck, J. Priller, M. Prinz, Microglia in the adult brain arise
from Ly-6ChiCCR2+ monocytes only under deﬁned host conditions, Nat.
Neurosci. 10 (2007) 1544–1553.
